{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000003","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.527903+00:00","generated_at":"2026-06-06T22:26:01.488872+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21","bullets":["Revenue estimated $827-832M; royalties $445-450M for FY2023.","Net income $292-297M; EBITDA $435-440M; adjusted EBITDA $425-430M.","GAAP diluted EPS $2.18-2.21; non-GAAP diluted EPS $2.77-2.80.","Preliminary unaudited estimates subject to completion of year-end close."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000003","json":"https://secwatch.observer/filing/0001159036-24-000003.json","markdown":"https://secwatch.observer/filing/0001159036-24-000003.md","text":"https://secwatch.observer/filing/0001159036-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/halo-20240117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:26:01.488872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36230b0984b9aa7e75907b0ac1a1f9afc64f5c30","claim":"HALOZYME THERAPEUTICS, INC. reported Twelve Months Ended December 31, 2023 results: revenue $827 million to $832 million, net income $292 million to $297 million, EPS GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80.","evidence_excerpt":"this preliminary information. Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2023 The Company estimates 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates 2023 royalties will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income will be in the range of $292","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000003/0001159036-24-000003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Twelve Months Ended December 31, 2023"},{"label":"Revenue","value":"$827 million to $832 million"},{"label":"Net income","value":"$292 million to $297 million"},{"label":"EPS","value":"GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}